

Notice of Allowability	Application No.	Applicant(s)	
	09/639,207	KAZEMI-ESFARJANI ET AL.	
	Examiner	Art Unit	

Daniel M Sullivan

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included
 erewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS
 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative
 of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to the Paper filed 19 May 2004.

2. The allowed claim(s) is/are 26,29-32,34,37-40,42,44-46 and 50.

3. The drawings filed on 19 May 2004 are accepted by the Examiner.

4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the
 International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements
 noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF
 INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 1) hereto or 2) to Paper No./Mail Date _____.
 (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of
 Paper No./Mail Date _____.
 Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of
 each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the
 attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)

2. Notice of Draftsperson's Patent Drawing Review (PTO-948)

3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
 Paper No./Mail Date _____

4. Examiner's Comment Regarding Requirement for Deposit
 of Biological Material

5. Notice of Informal Patent Application (PTO-152)

6. Interview Summary (PTO-413),
 Paper No./Mail Date _____.
 7. Examiner's Amendment/Comment

8. Examiner's Statement of Reasons for Allowance

9. Other _____.

Anne-Marie Falk
ANNE-MARIE FALK, PH.D
PRIMARY EXAMINER

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Joseph Baker on 2 June 2004.

The application has been amended as follows:

In the claims

Cancel claims 47-49 and 51-79.

Amend claims 42, 46 and 50 as follows:

42. (Currently Amended) The *D. melanogaster* of claim 26, wherein the Drosophila further comprises a marker sequence inserted into its genomic DNA, wherein the marker is located adjacent to a gene selected from the group consisting of a HDJ1 gene, a TPR2 gene, and a MLF gene in the animalDrosophila, and wherein the marker sequence comprises an inducible upstream activating sequence, a minimal promoter sequence and 5' and 3' transposon elements containing terminal inverted repeats.

46. (Currently Amended) The *D. melanogaster* of claim 42, wherein the marker sequence is near
adjacent to an MLF gene.

Art Unit: 1636

50. (Previously Presented) A method of producing a transgenic *D. melanogaster* characterized by suppressed polyglutamine toxicity comprising:

(a) transforming a *D. melanogaster* embryo or fertilized egg with a transgene comprising a plurality of CAA and CAG sequences encoding a polyglutamine sequence operably linked to a constitutive, regulatable, or tissue specific expression control element, wherein the tissue specific expression control element is selected from the group consisting of *Appl*, rhodopsin 1 promoter, and GLASS transcription factor element and

(b) selecting a *D. melanogaster* that exhibits polyglutamine toxicity.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel M Sullivan whose telephone number is 571-272-0779.

The examiner can normally be reached on Monday through Thursday 6:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DMS

Anne-Marie Falk
ANNE-MARIE FALK, PH.D.
PRIMARY EXAMINER